Lacosamide Glenmark

Lacosamide, the active ingredient in Lacosamide Glenmark, is an antiepileptic presented as an oral tablet for oral use. It treats partial‑onset seizures in adults and children. GNH USA supplies Lacosamide Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic indicated for the treatment of partial‑onset seizures.

- Partial‑onset seizures: reduces seizure frequency as adjunctive therapy. - Focal seizures: provides additional seizure control when combined with other antiepileptics. - Epilepsy (partial seizures): improves overall seizure management in patients with refractory epilepsy.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Fatigue: unusual tiredness or lack of energy. - Headache: mild to moderate pain in the head. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythms, including atrial fibrillation. - Severe allergic reactions: anaphylaxis or angioedema. - Liver injury: signs of hepatitis or elevated liver enzymes. - Respiratory depression: difficulty breathing, especially with concomitant CNS depressants.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Renal impairment: adjust dosing in patients with reduced kidney function. - Hepatic impairment: use caution and consider dose modification in liver disease. - Cardiac conduction disorders: monitor ECG for PR‑interval prolongation. - Concomitant antiepileptics: assess for additive CNS effects. - Pregnancy and lactation: weigh benefits against potential unknown risks. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lacosamide plasma levels. - Carbamazepine: enzyme induction may reduce lacosamide concentrations. - Other sodium‑channel blockers: heightened risk of CNS depression.

Moderate Interactions (Monitor Closely): - Valproate: may affect seizure control when combined. - Oral contraceptives: potential reduction in hormonal efficacy. - Antihypertensives: possible additive blood pressure lowering effects.